![Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2039278134/2052876698/gr4.jpg)
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB
![Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer - ScienceDirect Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1542356519312388-gr2.jpg)
Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer - ScienceDirect
![Table 1 from Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar Table 1 from Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/66b1cd66c5a66439bb3847578e78918661a4df89/4-Table1-1.png)
Table 1 from Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig1_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig2_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a96fc01f495907ea18214fdc7db7ffd9b210d72c/2-TableI-1.png)
PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar
![Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1499387218300900-gr4.jpg)
Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect
![Diseases | Free Full-Text | Diagnostic and Prognostic Value of CEA and CA19- 9 in Colorectal Cancer | HTML Diseases | Free Full-Text | Diagnostic and Prognostic Value of CEA and CA19- 9 in Colorectal Cancer | HTML](https://www.mdpi.com/diseases/diseases-09-00021/article_deploy/html/images/diseases-09-00021-g001-550.jpg)
Diseases | Free Full-Text | Diagnostic and Prognostic Value of CEA and CA19- 9 in Colorectal Cancer | HTML
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer. - Abstract - Europe PMC Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3868680/bin/jkss-85-283-i001.jpg)
Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer. - Abstract - Europe PMC
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/65458672-7722-4ca7-a49b-92f13c344a05/gr1_lrg.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/774e78614b2aab775f3493d19d9ef2cdd99429ad/3-Table1-1.png)
The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar
![CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube](https://i.ytimg.com/vi/eOWd34Q2NoM/maxresdefault.jpg)